Although further research is required to clarify the mechanisms underlying the anticancer effects of metformin, the present study demonstrates that the inhibition of the Shh signaling pathway is a significant contributing factor to the anticancer effects of metformin in breast cancer. The gene discussed is SHH; the disease is breast carcinoma.